MedTrace Logo

Early In-hospital Initiation of Pharmacotherapy for Smoking Cessation, Patients After ACS

NCT02106637 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2017-12-05

No results posted yet for this study

Summary

The hypothesis of this study is that combination of Varenicline treatment with nurse-led hospital support during hospitalization and after discharge will result in clinically significant higher long term abstinence rates in smokers with ACS, as compared with nurse led support and placebo, without a significant increase in the risk of adverse events.

Conditions

  • Acute Coronary Syndrome
  • Smoking Cessation

Interventions

DRUG

Varenicline

drug will be initiated during hospitalization and continued for 12 weeks following discharge

DRUG

placebo

placebo

Sponsors & Collaborators

  • Hadassah Medical Organization

    collaborator OTHER

  • Barzilai Medical Center

    collaborator OTHER

  • Sheba Medical Center

    lead OTHER_GOV

Principal Investigators

  • Ilan Goldenberg, Prof. · Sheba Medical Center

  • Haim Lotan, MD · Hadassa medical organisation

  • Haim Yosefi, MD · Barzili Medical Center

  • Robert Klempfner, MD · Sheba Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2018-08-31
Completion
2018-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02106637 on ClinicalTrials.gov